Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 23 Publications

8 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    HepG2 cells were pretreated with Z-VAD-FMK for 2 hours followed by treatment with IsoA for 16 hours, and the apoptotic cells were evaluated and quantified by Annexin V/7-AAD staining and flow cytometry. The mean±SD of three experiments is shown.***, P < 0.001

    Cancer Res, 2017, 77(4):926-936. Z-VAD-FMK purchased from Selleck.

  • MM.1S cells were incubated with or without pan-caspase inhibitor Z-VAD-FMK for 1 h and then treated with DCZ3301 (4 μM) for 48 h followed by assessment of cell apoptosis using Annexin V/PI staining. Columns (right panel) represent the average percent of Annexin V positive cells from three independent experiments, which are shown as the mean±SD.

    Theranostics, 2017, 7(15):3690-3699. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • Z-VAD-FMK (ZVF) reversed K562 cell apoptosis induced by imatinib (IM) and/or hUC-MSCs-Exo. **P < 0.01 versus K562 + IM group, ##P < 0.01 versus K562 + IM + hUC-MSC-Exo group.

    Cytotherapy, 2018, 20(2):181-188. Z-VAD-FMK purchased from Selleck.

    (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

  • Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

    Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a MXTBdI9xfG:|aYOgRZN{[Xl? MYe1NO69VQ>? NFr3blMzPGh? NVHZc|RmcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? MVKyOlE3QTB5NR?=
HGL5 NUTQdJVKSXCxcITvd4l{KEG|c3H5 NHXRWYk2OM7:TR?= NGPvOYEzPGh? M3jCTolv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRm M4niPVI3OTZ7MEe1
HepG2 NFHKeIVCeG:ydH;zbZMhSXO|YYm= NV\tVHdMOjEQvF2= NYHVOHFiOWh? NVTjcmh6[XS2ZX71ZZRm\CC2aHWgZZBweHSxdHnjJIlv\HWldHnvckBw\iCLSVmtNVDDqA>? NVSweYNpOjZzNkS3PVU>
BEL-7402 NG[2bIpCeG:ydH;zbZMhSXO|YYm= NXrKdVJOOjEQvF2= NYnZ[GF4OWh? M1nqZ4F1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> MYiyOlE3PDd7NR?=
CEF NGniPYFMcW6jc3WgRZN{[Xl? M1\qcVAtOzNuNkesNVAx|ryP NInwWVgyPW2rbh?= NX;sVnpJ\G:5bj3y[Yd2dGG2ZYOgVHIh\W68eX3lJIFkfGm4aYT5JJRwKDRy78{FJIF1KDFyMN88US=> MXKyOlExOjN|OR?=
SP2/0 MW\BdI9xfG:|aYOgRZN{[Xl? NUHFcXo4OTByzszN MWCxbC=> NX7CeoxJTE2VTx?= MXPicI9kc3NidHjlJIFxd3C2b4Ppd{Bw\iCVUEKvNEBk\Wyucx?= Mlr2NlYxPzR5M{K=
HUVEC-2c NHXyNYdCeG:ydH;zbZMhSXO|YYm= NU\CcmpwPTEQvF2= NXz6NGpQPmh? MmLS[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> NX;OWGZqOjZyMkG3Nlk>
U1 MUnBdI9xfG:|aYOgRZN{[Xl? Ml7UNE0yODEQvF2= NIDMSVMzcA>? NY\UT4t6emWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXi4cZJXOjV7OEC5OFI>
ACH-2 NGTjTXNCeG:ydH;zbZMhSXO|YYm= M1zhZVAuOjByzszN NV\FTJpvOmh? M3Xa[JJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV6yOVk5ODl2Mh?=
U1 MUXLbY5ie2ViQYPzZZk> NFOyR4UyODEQvF2= M{P6XVJp M4f6NYlvcGmkaYTzJINie3Cjc3WtNy=> M3\IVlI2QThyOUSy
A549/V16 MX\BdI9xfG:|aYOgRZN{[Xl? MlrIOVDPxE1? NYPOSY4{OWh? MUfy[ZBz\XO|ZYOgWGcwXE1vaX7keYNm\CCjcH;weI9{cXN? NFPCfVIzPTl2NkCzNy=>
SGN MoTXRZBweHSxc3nzJGF{e2G7 NFGxO|AzOG2P NG\nXVc1QGh? MUHoZZMhdm9iaX7mcJVmdmOnIH;uJGFKTixiY3HsdIFqdiCneIDy[ZN{cW:wIH;yJINmdGxiYYDvdJRwe2m| NEXFWGgzPTh5NE[zNy=>
HCT116  NVvuOG4zSXCxcITvd4l{KEG|c3H5 NUjVc4dIPTEQvF2= NIn5PHozcA>? Mlu3bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDESHZR NXTTfWpVOjV6Nki4NVg>
DTK-SME MmixRZBweHSxc3nzJGF{e2G7 NFXxWJA2OM7:TR?= M2H2bFJp M4nTWWROW09? MnjxdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> M3PTWVI2QDR|OEm3
HL-60 Ml7IRZBweHSxc3nzJGF{e2G7 MVu1NO69VQ>? NGX1NlM1QGh? NVPweWJUemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? NFKyNYczPTh{NEC0Ny=>
U937 NXnsS4h1SXCxcITvd4l{KEG|c3H5 NGPNbGQ2OM7:TR?= MlvYOFhp NF64W|hz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? MUCyOVgzPDB2Mx?=
A549 NIXqfpNCeG:ydH;zbZMhSXO|YYm= MoLtNlAh|ryP MoTwNlRp NInlVmVz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KEiIQ2CgeJJm[XSvZX70 M1jT[VI2Pzl2MUS5
HeLa MYHBdI9xfG:|aYOgRZN{[Xl? MkfTNVDPxE1? MofsOFhp Mo\x[IVkdGmwZYOgeIhmKHKjdHWgc4Yh[XCxcITvd4l{KGS{YX3heIlk[WyueR?= M{TSUlI2Pzd{NUS1
SGC-7901 Mnu1RZBweHSxc3nzJGF{e2G7 NYXvXHpWOjEEoN88US=> MnXhNYg> MkD5bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> MX:yOVc3PzB5Nh?=
MCF-7 M2fTd2Fxd3C2b4Ppd{BCe3OjeR?= NGH5eo0yOM7:TR?= NInIZ40zcA>? MYPpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IEPC Mo\tNlU4OjJzMUS=
A549 NUK3[YlLSXCxcITvd4l{KEG|c3H5 M2P3XFExKM7:TR?= MlHONlRp NYXkOmZCTE2VTx?= M3fyNJBzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u MX6yOVY5OzV4OB?=
U87 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3lb|BWPTEQvF2= M3y4VFFp NGXmWnpz\WOxdnXyd{Bk\WyuIHfyc5d1cCCocn;tJHROYiC2cnXheI1mdnR? MnfmNlU3QDF4Nki=
Neocortical Neuron MkPIUoV2em:2b4jpZ4l1gSCDc4PhfS=> NXzXVYtDOTByzszN NXq5d2pVOWh? MofDZY51[Wexbnn6[ZMhUG:rYX3p[IUhSS2LbnT1Z4VlKE6ndYLveI95cWOrdIm= MWWyOVY4PTByMR?=
Primary human placental cytotrophoblasts M{fiemFxd3C2b4Ppd{BCe3OjeR?= NE\QW4I{OM7:TR?= Moj1NlRp MYDEUXNQ NFH2RY5z\X[ncoPld{B1cGViaX7obYJqfGmxbjDv[kAyOc7{LVjTSFIh[nlidILpZ4xwe2GwwrC= NFzicIgzPTZ2MkW5Ni=>
MM NIrzd3JCeG:ydH;zbZMhSXO|YYm= M3zK[|Ux|ryP NV7QZlRlOjCvaX6= M3n0WpBienSueTDpcohq[mm2czDTTGsucW6mdXPl[EAh[2WubDDk[YF1cA>? NITLRnczPTV|MEC5PC=>
DLD1 NH:2R|NCeG:ydH;zbZMhSXO|YYm= NX3NZZlzOjEEoN88US=> NGfL[IUycA>? NH;Ueohx[XK2bImgdoV3\XK|ZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGfTVFE> NH7NN20zPTV{NEK0Oi=>
MDA-MB-231 MYrDfZRwfG:6aXPpeJkhSXO|YYm= MoTlNVDPxE1? NYXxXWp5OWh? NXzPOY1r[XWpbXXueJMh[2WubDDk[YF1cCCjZoTldkBEUFWDIITy[YF1dWWwdB?= M17ZRVI2PTJzNUCx
MKN28 MYDBdI9xfG:|aYOgRZN{[Xl? MkTGNVDPxE1? M{PNclMxdWmw NF3KPYZFVVOR NW\uZ|ZFcW6qaXLpeJMhXE6ILd8xJJBtfXNiQ1jYMYlv\HWlZXSgZZBweHSxc3nz MlqyNlU2OTN7NkC=
HL-60 M13N[WN6fG:2b4jpZ4l1gSCDc4PhfS=> NYHpXJViOTByzszN M{XXTFFp MUHEUXNQ MUFCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy| NV;ieGJEOjV3MEK5N|I>
AGS MW\BdI9xfG:|aYOgRZN{[Xl? M4XWT|Ex|ryP MonTNYg> NU\sVoR3eHKndnXueJMh[3W{Y4XtbY4ucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID24MEBidmRiLUmgdJJwfGWrboO= M2f6NFI2PDl{MkG0
A549  MYDBdI9xfG:|aYOgRZN{[Xl? NH22Uo8yOM7:TR?= MVWyOIg> NFPDToxjdG:la4OgSG1CWy2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDhcoQh[XCxcITveIlkKGOnbHyg[IVifGh? M3K1R|I2PDN2OUi5
INS-1 MXXBdI9xfG:|aYOgRZN{[Xl? NFzVPZI2OM7:TR?= NX;hTFRnPmh? NYDsdmhoTE2VTx?= Mn\y[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8Li MUmyOVQ{ODh7Nx?=
Primary hepatocytes  MmnQRZBweHSxc3nzJGF{e2G7 M2H6T|Ux|ryP MX6xPIg> M3W4[olvcGmkaYTzJIFxd3C2b4Ppd{Bw\iCqZYDheI9kgXSnczDpcoR2[2WmIHL5JGFkfCCGIHHu[EBVVkZvzsG= MXWyOVQxPzV|OB?=
L929-A  NYfrSnp5S3m2b4TvfIlkcXS7IFHzd4F6 MXWyNOKh|ryP M{n0e|I1cA>? NF[4[5BqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHi= M{TrO|I2Ozl6NUSw
L929-N NX:3VVZFS3m2b4TvfIlkcXS7IFHzd4F6 M3rQbFIxyqEQvF2= NF\seIQzPGh? NVrOU|NM\W6qYX7j[ZMh\GWjdHigeoliKGG3dH;jdolv\SCWTldOtUBxem:mdXP0bY9v MUWyOVM6QDV2MB?=
Cytotoxicity Assay MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1e3O|Ix|ryP MUe0PIg> MoO3dJJmfmWwdDDNTG1FNWmwZIXj[YQh[2WubDDk[YF1cA>? MkDpNlU{QTJzMU[=
COS7 MmfkT4lv[XOnIFHzd4F6 NHLFRm8yOM7:TR?= MUSyOIg> MWfpcoNz\WG|ZYOgZ4F{eGG|ZTCzM|ch[WO2aY\peIlmew>? M{G4WlI2Ozh2MEK1
COS7 NUS0SnlxSXCxcITvd4l{KEG|c3H5 MV:xNO69VQ>? NFjXbW81QGh? NVW0T2tReGG{dHnhcIx6KHC{ZY\lcpRm\CCIQ{GwNU1qdmS3Y3XkJINmdGxiZHXheIg> MVmyOVM5PDB{NR?=
A375 NYW2fm93SXCxcITvd4l{KEG|c3H5 MVSzNO69VQ>? NXrNO2hnOmh? M3PDeJBz\X[nboTzJJRp\SCmcoXnMYlv\HWlZXSgVGFTWCClbHXheoFo\Q>? MUmyOVM4PjFzNR?=
A549 NF\o[m1CeG:ydH;zbZMhSXO|YYm= MkLYOVDPxE1? MnTWNlRp MULy[ZZmenOnczDybYJwe2:vZTDibY9o\W6nc3nzJIFv\CCjcH;weI9{cXNiY3H1d4VlKGK7IDDDbIlrd26pZHHu MmrRNlU{PDl5OEG=
A549 M2jEfmFxd3C2b4Ppd{BCe3OjeR?= M2nNcFIvPS1{Nd88US=> M1HNcFFp MYXk[YNz\WG|ZYOgeIhmKHCxcIXsZZRqd25ib3[gZZBweHSxdHnjJINmdGy|IHTldIVv\CCxbjDjc45k\W62cnH0bY9vew>? M1L0SlI2OzR{NEK3
 NBL-W-S  M3TLU2Fxd3C2b4Ppd{BCe3OjeR?= NYK2eXZiPTEQvF2= NWLXNllnOWh? Mln4[pVtdHlicnXzZ5VmeyClZXzsJJZq[WKrbHn0fUBi\nSncjDHRW5VNTZzIITy[YF1dWWwdB?= NULuXpcxOjV|MkOyNlI>
Caki-1  M3u3PWFxd3C2b4Ppd{BCe3OjeR?= MVe0NO69VQ>? MV60PIg> MXPy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz MlnONlUzPzlzOUG=
769-P M4nVXmFxd3C2b4Ppd{BCe3OjeR?= MonxOFDPxE1? NIf2VZg1QGh? NUXNT2RxemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NVnORZZvOjV{N{mxPVE>
H9c2 NWHNTIhnSXCxcITvd4l{KEG|c3H5 MVe1NO69VQ>? NIXwcmcycA>? MYXpcohq[mm2czDEU3gucW6mdXPl[EBk[XOyYYPlJFMh[WO2aY\heIlwdiCkdYSgco91KHSqZTDsc5N{KG:oIHPlcIx{ Ml3qNlUzQDN6MUm=
K562 NUTKZZpjSXCxcITvd4l{KEG|c3H5 M1u3RlUx|ryP Moi5OIg> M4HnXolvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> NGPQSYgzPTJ2MU[xPS=>
L929 NXS2[VdQSXCxcITvd4l{KEG|c3H5 MXWxNO69VQ>? M2S1d|Zp NV75PFdQcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? NV;hd21ROjVzOUW2OlA>
A549 NVLYWohbSXCxcITvd4l{KEG|c3H5 M{fhWFEx|ryP MmTYN4g> NWXlU3FjemWmdXPld{Bk\WyuIHHwc5B1d3OrczDjZZV{\WRiYomgVHFS M4Ha[VI2OTZzNkm5
MCF-7 Mo\qRZBweHSxc3nzJGF{e2G7 NV\vVmxzOjEQvF2= NGfWbXczcA>? Mlfh[IVkemWjc3XzJGtFWi2|aWLORU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NEHVS5gzPTF6MkK0NC=>
OS M{nkNGFxd3C2b4Ppd{BCe3OjeR?= NVjjVYNmOjBxNEFOwG0> MkjGO|Jp MX\pcohq[mm2czDPV{Bk\WyuII\pZYJqdGm2eTDy[YR2[3Srb36gZpkhSzZiY3XyZY1q\GV? MoXnNlUyPTJ|OUm=
HUVECs M33FNWFxd3C2b4Ppd{BCe3OjeR?= M2LW[VEx|ryP MnTWNog> MWdCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MUOyOVE{QDdyMx?=
EA.hy926 MV;BdI9xfG:|aYOgRZN{[Xl? MknCNVDPxE1? MlXKNog> NFHyN3TDqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEWDLnj5PVI3 Mn:5NlUyOzh5MEO=
Ebs NGnZVZpCeG:ydH;zbZMhSXO|YYm= MUmxNE0yODEQvF2= M3z6W|I1cA>? M2TV[:KhVU2WUzDn[Y5memG2aX;uJJJifGViZHXjdoVie2WmIHHzJJRp\SClb37j[Y51emG2aX;uJI9nKHpvVlHEMoZucyCrbnPy[YF{\WR? M2nDb|I2OTN2OEG3
Jurkat NYXTNWMxSXCxcITvd4l{KEG|c3H5 NFH3UnUzOM7:TR?= MXKyOIg> NGTSfldFVVOR NYHkcWhxeGG{dHnhcIx6KGmwaHnibZQh[2WubDDk[YF1cCCxZjDKeZJs[XRiY3XscJMhcW6mdXPl[EBjgSBzMEC1PE1HPCClb33ibY5m\CC5aYToJHZRScLi NHLHcI4zPTF{MEeyNy=>
K562 M4PJcWFxd3C2b4Ppd{BCe3OjeR?= M4\6NlAvOS1zzszN NFyzV5gycA>? MVzpcohq[mm2czDjcIVifmGpZTDv[kBJW1B7MDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoLlNlUyOTlzOEi=
IMR-32 MkfSRZBweHSxc3nzJGF{e2G7 M{fJblQxyqEQvF5CpC=> MYKybC=> NVn4W3Q4\GWlcnXhd4UhcW5iYYDvdJRwfGmlIHPlcIx{KGOxbYDhdoVlKHSxIGStNkB1d3irbh?= MkDUNlUxQDR5NUW=
RPMI 8226 NEjuUXdCeG:ydH;zbZMhSXO|YYm= M3zifVExOM7:TR?= NXfQcFlGOWh? MonSZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? M1TqbFI2ODN5OEWx
U266  NIPxfZJCeG:ydH;zbZMhSXO|YYm= MnnpNVAx|ryP NWjTTXdYOWh? M2HmVpBienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= NEHGTpgzPTB|N{i1NS=>
H929  M{S1UWFxd3C2b4Ppd{BCe3OjeR?= NWTlTlBCOTByzszN MmrJNYg> NUeyZopVeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x NGfDPHUzPTB|N{i1NS=>
MM.1S  MonERZBweHSxc3nzJGF{e2G7 MorqNVAx|ryP MWCxbC=> MV3l[oZq[2mnboTsfUBxemW4ZX70d{B{d3KjZnXubYIucW6mdXPl[EBk\WyuIHTlZZRpKGOxbXLpcoUhf2m2aDDu[YNzd3O2YYTpck0y NGDHd4QzPTB|N{i1NS=>
C6 MknQRZBweHSxc3nzJGF{e2G7 M1jCUlUx|ryP M4CyUVQ5cA>? M3;WPJBz\X[nboTzJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JINifXOnZDDifUBxemWpbnXuc4xwdmV? MXOyOVAyOzR5OR?=
AGS NVfVUIVMSXCxcITvd4l{KEG|c3H5 NFrOV4s2OM7:TR?= NWPrN4FDOjSq MlrYZYJwdGm|aIOg{tIudGGyYXPoc45mNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgbY5pcWKrdHXkJIdzd3e2aB?= NYPBbGJwOjVyMEm2PVg>
HeLa  NH;BdmxCeG:ydH;zbZMhSXO|YYm= NI\wPVM1OM7:TR?= M1;CVVI1cA>? MUPpcohq[mm2czD0bIUhcW6lcnXhd4VlKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIPpVm5HOTJz M2f6[|I1QTJ6Nki1
THP-1  MortRZBweHSxc3nzJGF{e2G7 Ml\YNVDPxE1? MVmxbC=> NFvGSWxz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEGOQT3TSHTDqA>? NXzlO|NIOjR7MkO2OVM>
P815  NW\SPFhPSXCxcITvd4l{KEG|c3H5 NXfBdYM1OTByINM1US=> MXWxNog> NGXZdHZFVVOR MlLTbY5pcWKrdIOgeolzfXNvaX7keYNm\CCjcH;weI9{cXN? MmT6NlQ6OjN{N{O=
HCT116 NXvuWGc6SXCxcITvd4l{KEG|c3H5 MXeyNO69VQ>? NYfGc204OjSq Ml7IZYJzd2ejdHXzJI9nKFSTLXnu[JVk\WRiYYDvdJRwe2l? Mln4NlQ5QTB2NEm=
SW1116  NIfDelVCeG:ydH;zbZMhSXO|YYm= NHvZeHMyOCEEtV2= M3q0bVFp M3focGROW09? NHT3dIRz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l Mn3WNlQ5PzR{OE[=
LOVO M2LRT2Fxd3C2b4Ppd{BCe3OjeR?= NIW4UIIyOCEEtV2= NHLKTIQycA>? NVvIR3VsTE2VTx?= MljjdoV{fHKjaX7zJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomg[4VncXSrbnniJJBtfXNiZHXjbZRi[mmwZR?= M3TF[FI1QDd2Mki2
SNU449  M1\6e2Fxd3C2b4Ppd{BCe3OjeR?= NHT6WVczOM7:TR?= NYL4N3JzPDiq NYDxOlRTTE2VTx?= NGr2cXZl\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> MnzsNlQ5PDF4M{i=
Caco-2 MnPMRZBweHSxc3nzJGF{e2G7 M2TC[|Qx6oDLzszN MnK4OIg> NUW1Wml5eHKndnXueJMhW1RvNz3pcoR2[2WmIGrPMVEh[2ijbnfld{BidmRiVFXSJIRzd3B? MXGyOFgzOjF6Mx?=
macrophage M1jDW2NmdGxiVnnhZoltcXS7IFHzd4F6 NVv6cHZHOC1{MEFOwG0> NHGweHczPGh? MWLpcoR2[2W|IGTOSk0h[W6mIGLpdFMu\GWyZX7k[Y51KG6nY4LvdJRwe2m|IHnuJI1i[3KxcHjh[4U> MmDJNlQ4QTl3NkW=
AGS  MmPIRZBweHSxc3nzJGF{e2G7 MnzFNlDPxE1? M{DG[lEzcA>? MVzEUXNQ MmWwdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBz\XOyb37z[UB1dyC2aHWgSZRQSWNiZoLhZ5Rqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnG3NlQ4QDl5MEO=
LCC9  MnvLR4VtdCCYaXHibYxqfHliQYPzZZk> M4njSFExOM7:TR?= NH;lSpo2\A>? M3:wRoJtd2OtczDj[YxtKGSnYYToJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25iTEG3JIFv\CClaHzvdo9yfWmwZR?= MXKyOFc5PTJ3Nh?=
U937  MlPNcoVkem:ydH;zbZMhSXO|YYm= MkPVNVDDqM7:TR?= MXWzNOKhdWmw NGj6d|BqdmS3Y3XzJI5m[3KxcITvd4l{KGOxbXLpcoUhf2m2aDDUUmY> M2D6RVI1Pzd|N{W2
T cell MWrD[YxtKHC{b3zp[oVz[XSrb36gZZN{[Xl? MmLSNE0yODEQvF2= M3vGRlczcA>? NGDVdFdKSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= MV[yOFc3QDdyNx?=
HeLa  NFvUPHNCeG:ydH;zbZMhSXO|YYm= NE\XU2Q2OM7:TR?= M3;DZlczcA>? M33mSmROW09? NUf3boM6eHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>? NHvWeI0zPDd3NEe4Oi=>
HeLa  NYTTXnVFSXCxcITvd4l{KEG|c3H5 M{HHd|ExOM7:TR?= MWOyOIg> MUDzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> MWeyOFczOjR4OB?=
IEC-6  MX7BdI9xfG:|aYOgRZN{[Xl? NX35U2hOOTEQvF2= NVu4fHp5OjSq MlzYdJJmfmWwdIOgWINlSS2rbnT1Z4VlKGOjc4Dhd4UuOyClbHXheoFo\SCjbnSg{tIu[2G2ZX7pckBl\We{YXTheIlwdg>? NWDjbHdxOjR5MUG1O|E>
HCT116 NWfjc4hMSXCxcITvd4l{KEG|c3H5 NW\nUm9ROjEQvF2= NE\Xb|MzPGh? Mm\JbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 MlWwNlQ4OTN6MUK=
L02 NUPoXGw4SXCxcITvd4l{KEG|c3H5 MWOyNO69VQ>? M2PPOlFp MmnYdJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?= NE\sbJYzPDdyNkS2NS=>
A375 M4DtbmFxd3C2b4Ppd{BCe3OjeR?= NH3HcIEzOM7:TR?= NHXDToUzPGh? NF62fJJz\X[ncoPld{BlcWOrdILpco9v\SCELXnu[JVk\WRiYYDvdJRwe2m| M1PCZlI1Pjl7MUGx
HDPC NXLXVJY5SXCxcITvd4l{KEG|c3H5 NIrkSJg2OML3TR?= NUjvb49UOjSq NYnNUGVlcW6qaXLpeJMhVk9vaX7keYNm\CCjcH;weI9{cXN? M{nn[FI1PjN2NUmz
A549 NXexV2w{SXCxcITvd4l{KEG|c3H5 M4Lp[|UxyrWP MmrHNog> NFjPcGRFVVOR MYHwdoV3\W62czD0bIUhcHmyb3TpdIxwcWRiRF7BJINwdnSnboSgdIhie2ViaX7keYNm\CCkeTDj[ZBp[WyxY3jyc41qdg>? NGTOS3UzPDV6OEGzOS=>
 BV-2 NGTRc49CeG:ydH;zbZMhSXO|YYm= MnPhNlDPxE1? MnX4Nog> M2\Nc5N2eHC{ZYPz[ZMhXVZvaX7keYNm\CClaILvcYF1cW5iZYj0dpV{cW:wIHHu[EBlcWyjdHnvckBw\iC2aHWgcpVkdGWjcjDlcpZmdG:yZR?= NF;yXm0zPDV3OEGxPC=>
HT-29  M1;2dmFxd3C2b4Ppd{BCe3OjeR?= MljjOVDPxE1? MV:0PIg> NVi4ZmRU[myxY3vzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDrZYVueG[ncn;s NFvpNYkzPDV2OUG3OS=>
A549 MnTSRZBweHSxc3nzJGF{e2G7 MUK1{txO NFjadoczPGh? NF7ET2t{fXCycnXzd4V{KD[nwrCoRmsyODB2MDmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> NFXBfZAzPDV{OUi3NS=>
MIA-PaCa-2 MmfERZBweHSxc3nzJGF{e2G7 M{LRc|I1cA>? MWricI9kc3NiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIlv\HWlZXSgZpkh[m:2aDDBMVQ1OzZ3NDDhcoQheGGlbHn0ZZhmdA>? MlO4NlQ2OTB7OUK=
Caki-1 NHvG[WZCeG:ydH;zbZMhSXO|YYm= NWnNc5c{OjEQvF2= NXzHNHFLOWh? MXzpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> MYmyOFUxPDZ6MR?=
CLL MYfBdI9xfG:|aYOgRZN{[Xl? M3v1fVI2|ryP NIezSI8ycA>? M4LUUZBienSrYXzsfUBjdG:la4OgUWxPOjJ|OD3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ MYWyOFQ3PzZ|NB?=
SGC-7901 NFvqd25CeG:ydH;zbZMhSXO|YYm= MWKxNO69VQ>? NVvkVm5yOjSq MXvwdo9ud3SnczD0bIUhS0eLST3pcohq[mm2ZXSgZ4VtdCCpcn;3eIghcW5iU1fDMVc6ODFiY3XscJM> M37FflI1PDV2NEi4
k1735 MlfuRZBweHSxc3nzJGF{e2G7 NF\IdYUzOOLCid88cS=> NXqzNnZRPGh? NXTSbGNkcW6qaXLpeJPDqFOjbH3vcoVtdGFvaX7keYNm\CCjcH;weI9{cXN? NHL2[mIzPDR3MUGxOi=>
HaCaT  NG\xeIpCeG:ydH;zbZMhSXO|YYm= NE\r[2MyODEQvF2= Ml22NYg> NWXKPXNS[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=> NHLyT4ozPDN3Nkm5Oy=>
podocytes MUnBdI9xfG:|aYOgRZN{[Xl? NV[wNHA3OjByzszN M3P2U|Zp MXrpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA{NDRvRFfF Mnv2NlQ{Ozd5N{e=
 KB M{LvO2Fxd3C2b4Ppd{BCe3OjeR?= MmXFOVDPxE1? MnTsNlRp M37OR4lvcGmkaYTzJGxq[29vQT3pcoR2[2WmIHPhd5Bie2VvMzDhcoQhWEGUUDDhZ5RqfmG2aX;u M1zMeVI1OzN5NEmy
 HepG2  M{\TVGFxd3C2b4Ppd{BCe3OjeR?= M1PrdlEx|ryP NUTl[49vOjSq NYLDN5pmemWmdXPld{B3cW2nboTpckBkdGWjdnHn[UBk[XW|ZXSgZpkhVFCV MXiyOFMzPThzNh?=
fetal rat lung fibroblasts  MlXET4lv[XOnIFHzd4F6 NInmd2w5OM7:TdMg MVSxbC=> NVzycplZcW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? NUfXRVhOOjR|MUSxN|U>
PDL fibroblasts Moj3T4lv[XOnIFHzd4F6 MonHPFDPxE4EoB?= NH\FUIQycA>? MkXBbY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> MVGyOFMyPDF|NR?=
MB49 MVzBdI9xfG:|aYOgRZN{[Xl? NYmxc4FvOjEQvF2= MnriNYg> NYHCOnR2emW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq NFziSZczPDJ6MkSzNy=>
5637 M3TqdWFxd3C2b4Ppd{BCe3OjeR?= NWDico9KOjEQvF2= M{DDfFFp M3TQdJJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? NIHTTXkzPDJ6MkSzNy=>
A549  NUSxUm5VSXCxcITvd4l{KEG|c3H5 MYixNFDPxE1? M2jub|Q5cA>? MoXnd5VxeHKnc4Pld{B1cGViYYDvdJRwe2m|IHPheZNm\CCkeTDwbZBmemmwZdMg MVmyOFI4OjJyMR?=
MCC-2 NFvqfolCeG:ydH;zbZMhSXO|YYm= MWCyNEDPxE1? NHrDUpE3cA>? MUDEUXNQ M3LoW4Jtd2OtczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmViYYDvdJRwe2m|IHPlcIwh\GWjdHi= MYSyOFI3OjZ3OB?=
ADF Ml70RZBweHSxc3nzJGF{e2G7 MXO0NO69VQ>? Ml21Oog> NGPjVYZqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> MoHtNlQzOjh{M{K=
 U373  MnuzRZBweHSxc3nzJGF{e2G7 NUfV[oNGPDEQvF2= MW[2bC=> M2[1OIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NHnMNpgzPDJ{OEKzNi=>
RKO-HIPK2i NVu2WYJESXCxcITvd4l{KEG|c3H5 M2T4dVQx|ryP NVH5ZZdOPmh? NUewclF6cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> MmrrNlQzOjh{M{K=
HEC-1B M2HqeWFxd3C2b4Ppd{BCe3OjeR?= NX6wS2I1OjEQvF2= NXzh[YxyOWh? Mn;kdoVlfWOnczDUVE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUm= NFe1boszPDJzM{O1PC=>
4T1 Ml61R4VtdCCYaXHibYxqfHliQYPzZZk> NVrvR2FKOi53LUGw{txO M{[2[lRp NITjVnRFVVOR NWXuO49JemW|Y4Xld{B1cGViY4n0c5RwgGmlaYT5JI9nKDSWMTDj[YxteyCrbnT1Z4VlKGK7IGPQSHQhcW5iYTDjc45k\W62cnH0bY9vKGSncHXu[IVvfCCvYX7u[ZI> Ml7oNlQzODZzNkG=
OS  MVHBdI9xfG:|aYOgRZN{[Xl? NFH6eoIzOM7:TR?= NHTo[2s1cA>? NUi3dZl3cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JHBFXA>? NVTifpc6OjR{MES5N|c>
RPE NXrsN2ZHSXCxcITvd4l{KEG|c3H5 M37oNlExOM7:TR?= NXnrPVYxPDiq NWHFbHBseGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:w NUXVSXRIOjR{MEKwOVI>
UD29a Ml71RZBweHSxc3nzJGF{e2G7 M{jNcFUx|ryP M{fDflI1cA>? NYrzcll[cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JG5WXDN? NInaWYszPDF7MEW3OC=>
SH-SY5Y  MX7BdI9xfG:|aYOgRZN{[Xl? MVOxNO69VQ>? MXSyOIg> NFHzSIxifHSnboXheIV{KGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KEiQRT2ySGc> M3;UTlI1OTR3NE[z
HeLa  MX;BdI9xfG:|aYOgRZN{[Xl? M2XHUVExNzJyzszN M4r6TFI1cA>? MofubY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIITo[UBu[Wqxcnn0fUBw\iC2aHWgcYVu[mW{czDv[kB1cGViY3HzdIF{\S2oYX3pcJk> NUfYV2k2OjRzM{eyOlY>
SCCVII  M3jQdmFxd3C2b4Ppd{BCe3OjeR?= MorFNlXPxE1? M2DJO|Fp M17RT4lvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmk NH;OSHQzPDF{NkS2OC=>
RAW 264.7 MWfBdI9xfG:|aYOgRZN{[Xl? M3XFN|Ix|ryP NVXNRnFROTiq NUjVVZV2cW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?= MoqzNlQyOTZ5MEe=
A549  MojzRZBweHSxc3nzJGF{e2G7 MnHFNk42|ryP MVeyOIg> NH;SOZZl\WO{ZXHz[ZMhd3KrZH;ubY4ucW6mdXPl[EBifXSxcHjh[5kh[XNid3XscEBidmRiTH;zd{Bw\iEQlN-IcUBidHOxIH;jZ5VzemWmIHT1dolv\yCjdYTvdIhi\2mlIIDyc4Nme3N? MkO5NlQyODJ3MkK=
UM-SCC-10A  NF74S2JCeG:ydH;zbZMhSXO|YYm= MX[1NOK2VQ>? M1nDXFJp M1PBZZJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> MXuyOFA6QDd3Mx?=
BGC-823 Ml3mRZBweHSxc3nzJGF{e2G7 NV71XJNWOTBizszN NUDOVYY2OjSq MlfsdoVlfWOnczD0[ZRz[W6mcnnu[U1qdmS3Y3XkJIFxd3C2b4Ppd:Kh Mo\tNlQxQTh3MUG=
Nalm-6  M{m0U2Fxd3C2b4Ppd{BCe3OjeR?= Mn;nNlDPxE1? MVW0bC=> NIHaXFJqdmirYnn0d{Bk[XOyYYPlMVgh[W6mIHPhd5Bie2VvMzDhZ5RqfmG2aX;uJIFv\CCSQWLQMVEh[2ynYY\h[4U> NXqxW3R7OjRyM{m5Olc>
KHOS  MnrrRZBweHSxc3nzJGF{e2G7 NWPPS3dIPDEQvF2= MmjPNlRp NHXNOItjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg Mki0NlQxOjV|NkG=
G292 NXixfGl7SXCxcITvd4l{KEG|c3H5 MmfMOFDPxE1? MUCyOIg> NHrDXVBjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg MWGyOFAzPTN4MR?=
MG-63 NH\GUmxCeG:ydH;zbZMhSXO|YYm= M3rDUlQx|ryP M1zJeFI1cA>? MVHicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li MUmyOFAzPTN4MR?=
EBV-transformed B cells NUjtO3lLSXCxcITvd4l{KEG|c3H5 MlvHNlDPxE1? M3\IOFJp MlfLSG1UVw>? NGT2NWhjdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? NX30bYxTOjRyMEi2Nlg>
IM-9 B MUHBdI9xfG:|aYOgRZN{[Xl? M33DVVIx|ryP M1XTN|Jp NH;Zb|BFVVOR M{XKOoJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? NYe3fXMzOjRyMEi2Nlg>
CNE1 NInHRWxCeG:ydH;zbZMhSXO|YYm= NWradGhFOjEQvF2= M1;rc|Q5cA>? MkHCZoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> MXSyN|k5PTB{OR?=
CNE2 MmLSRZBweHSxc3nzJGF{e2G7 NF;rTmkzOM7:TR?= NVv6VXpjPDiq M3fueoJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ NWOwRmhXOjN7OEWwNlk>
HL-60 MXvBdI9xfG:|aYOgRZN{[Xl? NXLEfo5qPTEEtV2= M1rRSlFp NGC1O4lFVVOR NGXtdldqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEQUG0OS=> NU\HOWhSOjN7NEi3OVE>
L929 M4TXZWFxd3C2b4Ppd{BCe3OjeR?= M2fnfFEvOjYkgKO1xsDPxE4EoB?= MWGyOIg> NFzkSnBifWevZX70d{BVVkcQsT3pcoR2[2WmIH7lZ5JweHSxc3nzJIFv\CCjdYTvdIhi\3l? NIC4cJQzOzl2MUe2PS=>
Jurkat NX7jdZZkS2WubDDWbYFjcWyrdImgRZN{[Xl? NXPqeHl{Os7:TR?= MUO0bC=> NFHaOlhz\X[ncoPld{Boem:5dHigbY5pcWKrdHnvckBidmRizsKtZ4F1\W6rbjDk[YNz\WG|ZTDifUBJWy2DU1G= MlLvNlM5QTZyNkG=
RAW264.7  MULBdI9xfG:|aYOgRZN{[Xl? NH;NcG0yOCEQvF2= MV2yOIg> NVrIUpVT\GWlcnXhd4V{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBISQ>? NGTH[WwzOzh{MEKwNy=>
A431  NV7sV|RzU2mwYYPlJGF{e2G7 NFTUTlU1OM7:TR?= Ml3wNog> NGniSYZjdG:la4Og[ol{\XSrbj3pcoR2[2WmIHPs[YF3[WenIH;mJINie3Cjc3XzJIFv\CCSQWLQ MlfhNlM5ODByNUi=
Jurkat NXn1epFlS2WubDDWbYFjcWyrdImgRZN{[Xl? M4XoW|I2NTFyMN88US=> MlW5Oog> MkXMbY5pcWKrdIOgfk1HSS2FTVutbY5lfWOnZDDj[YxtKGSnYYTo MojUNlM6OzN3M{K=
COS-7  MlXjSpVv[3Srb36gRZN{[Xl? NILG[482OML3TR?= M{LEXlI1cA>? NIXpOG5i\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| NGnkVmYzOzl|M{KwPC=>
CAL27 NEPQUJRCeG:ydH;zbZMhSXO|YYm= MYCxNEDPxE1? M1zQVFJp MUPzeZBxemW|c3XzJGN2ei2QUIOtdoVlfWOnZDD2bYFjcWyrdImgZpkhfXBidH:gPVAm M2jKd|I{QTF5M{m2
THP-1  MYHBdI9xfG:|aYOgRZN{[Xl? M{\QTFExNTVyzszN NH;aUHAzcA>? Mn;sbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? MXyyN|kxODJ7OR?=
K562 NUTLcZlCSXCxcITvd4l{KEG|c3H5 NVHQc4VYOjEQvF2= MoDtOFhp MmHEbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhPC2PVR?= NXjSSGFnOjN6N{[4NlY>
HL-60 MoDxRZBweHSxc3nzJGF{e2G7 NGPiZogyODEQvF2= NEnzTWkzPGh? NXi4SFA{cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliYXLp[ZRidmViZHn0[ZJx\W6nc9Mg Mn;3NlM5PjV5N{i=
HeLa  M{j3UWFxd3C2b4Ppd{BCe3OjeR?= NGrjRmgzOM7:TR?= MWeybC=> NX7wbZhJcW6qaXLpeJMhTE2PUDDpcoR2[2WmIHHwc5B1d3Orcx?= M1rhNlI{QDZ|OU[2
U251 NHzMZ2RCeG:ydH;zbZMhSXO|YYm= MUeyNO69VQ>? Mnm5NlRp Ml\4bY5pcWKrdIOgZ4F{fGmlaX6gbY5lfWOnZDDHNk9OKHCqYYPlJIFzemW|dDDhcoQh[XCxcITvd4l{ MlH2NlM5OTZ6MU[=
HL-60 MmfpRZBweHSxc3nzJGF{e2G7 MnjHOVDDvU1? MW[0bC=> M2\mTYJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?= MmnqNlM5ODR5ME[=
Ec-109 Mo[1RZBweHSxc3nzJGF{e2G7 NFfJdWcyOCEQvF2= M37KTFQ5cA>? NULkRVdyemWycnXzd4V{KFCHLX3l[IlifGWmIFXjMVExQSClZXzsJIFxd3C2b4Ppdy=> Mk\INlM4QDJ4NEG=
RKO MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4TTNVExKM7:TR?= MmDUNlRp NILJVJVqdmirYnn0d{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliY3H1d4VlKGK7IFTBRi=> Mn\1NlM4PThyNkS=
T98G MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2nRNlEuOTByzszN NV;ZWIxqOjSq MmDTbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NFv4O5AzOzd4OUK3OS=>
Jurkat Ml;3R4VtdCCYaXHibYxqfHliQYPzZZk> M{DvR|ExOC1{MEFOwG0> NHLDS5UzPGh? NIL0cYFqdmirYnn0d{BJ[UF2IHnu[JVk\XNiYYDvdJRwe2m|IHTldIVv\GWwdDDv[kBkd26lZX70doF1cW:wwrC= NFjpXVQzOzd|MkS4NS=>
Molt-3  NGT2b4xCeG:ydH;zbZMhSXO|YYm= MWm1NO69VQ>? MYSybC=> MmDVdoVlfWOnczDt[YxifG:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MkWzNlM4OjVyMUO=
hMSC12 NGmxTHpCeG:ydH;zbZMhSXO|YYm= NFjydpgyODEQvF2= NWjLe4lGPGR? M{XXV4lvcGmkaYTzJI9{fGWxZ3XubYMh[3WudIXy[U1qdmS3Y3XkJINmdGxiZHXheIgh[W6mIHPhcINq\mmlYYTpc44> MnvvNlM3PTd6MkK=
HM7  Mk\qRZBweHSxc3nzJGF{e2G7 MX6yNO69VcLi M1XMSlFp NWKwfZdj[myxY3vzJIFxcWO3bHHy[Y4hSSCjY3X0ZZRmNWmwZIXj[YQh[2G|cHHz[U0{KGGldHn2ZZRqd25iYX7kJHBCWlBiY3zlZZZi\2V? MWOyN|U5OzRzMh?=
Hep-2  M{HkfWFxd3C2b4Ppd{BCe3OjeR?= NW\aS5VoOjEQvF5CpC=> Ml3FNlRp M2K5eWROW09? Ml7YZYxt\X[rYYTld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDzbYxq[mmwaX6= MWCyN|U5ODB|Mh?=
HSCs NInRZoVCeG:ydH;zbZMhSXO|YYm= NYTkfYFYPTEQvF2= M4HhN|I1cA>? NWi3O|dETE2VTx?= M1X4[YlvcGmkaYTzJI5qdG:2aX7pZk1qdmS3Y3XkJGRPSSCmYX3h[4UhcW6maXPheIVlKGK7IGDBVnAh[2ynYY\h[4U> NVGzepdPOjN2OUm4O|Q>
HL-60  NVLiN|ZYS3m2b4TvfIlkcXS7IFHzd4F6 Mof3NlDPxE4EoB?= M2TXS|I1cA>? NIj2XWNz\WS3Y3XzJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIFXyfVU> M{HXOlI{PDl2NEiw
HA NYTBb2xlSXCxcITvd4l{KEG|c3H5 NXTpVFk4PTEQvF2= MYeyOIg> MUXzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE> MXSyN|Q4PTl3Nh?=
C666-1 MlL0RZBweHSxc3nzJGF{e2G7 NVLH[VBbPTEQvF2= MVmyOIg> NFLjXm9{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? MkLxNlM1PzV7NU[=
Hepa1-6 NHHyUIhCeG:ydH;zbZMhSXO|YYm= Ml;iOVDPxE1? M2\6V|Jp MnS1bY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m| MWOyN|Q1Pjd3Mx?=
PLC/PRF/5c MXjBdI9xfG:|aYOgRZN{[Xl? MnKxOVDPxE1? NV7sV|Z2OWh? NE[1Xo1xemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=> M3P5XVI{PDN6OEK0
HCT116 Mn7jRZBweHSxc3nzJGF{e2G7 NFq1d4gyODEQvF2= NFnuTmQyNjWq NYewcJJMcW6qaXLpeJMhV3NvaX7keYNm\CClZXzsJIRm[XSq NHn1[WwzOzd2NEO1Ny=>
HCEC NYnLdXUzTnWwY4Tpc44hSXO|YYm= MV:1NO69VQ>? MoOxO|Jp Mn;jSG1UVw>? NWPuTmVXemW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>? NHHMUnkzOzd2MkCxNS=>
Primary rat cerebral cortical neurons MXHBdI9xfG:|aYOgRZN{[Xl? NVnKPFlrOTByzszN MmrRNYg> MoHGdJJmfmWwdIOgR4QucW6mdXPl[EBieG:ydH;zbZMh[W6mIHPlcIwh\GWjdHi= NFzYW3QzOzd2MUOxOy=>
MDA-MB-231  M{XBVGFxd3C2b4Ppd{BCe3OjeR?= M3HIS|I2|ryP MnfUNlRp NFfBcWxi[nKxZ3H0[ZMh[3m2b4TvfIlkcXS7IHHu[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDS[|M> M362dlI2OzN5NUS0
NLRP3-Tet-on-MC/9  M1PhW2Fxd3C2b4Ppd{BCe3OjeR?= NYT2do9WOTBvNEFOwG0> NETEcpMyOmh? M1rGZoF1fGWwdXH0[ZMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JGNCWFNvYYPzc4Nq[XSnZDDOUHJROyCvdYThcpR{KGmwIITo[UBV\XRvb36gd5l{fGWv NHnxUngzOzdyM{O4PS=>
KNS42  M2C5cGFxd3C2b4Ppd{BCe3OjeR?= Mly3OVDPxE1? MkHvNYg> MoG4doVlfWOnczDj[YxtKGSnYYToJIFv\CClb33wcIV1\Wy7IHHic4xqe2inZDDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBqdiC{ZYPwc45{\SC2bzDBRnQuOjZ|L{LES{9u\XSob4LtbY4h[2:vYnnuZZRqd25? NGjD[XIzOzZ7MUG0OS=>
MCF-7  NYfv[4NXSXCxcITvd4l{KEG|c3H5 MXiyNO69VcLi NUPUUYQzPzKq NVnFRVZRcW6qaXLpeJMh\XG3b3ytJIFv\CB2LV;IWE1u\WSrYYTl[EBieG:ydH;zbZM> NUS0WW9bOjN4N{W2OFM>
hCMEC/D3  NVTnfYJ4SXCxcITvd4l{KEG|c3H5 MkLYNlXPxE1? M3LDVVczcA>? M4fjb5Jm\HWlZYOgUJR5SSCrbnT1Z4VlKGGyb4D0c5Nqew>? NXvMd2JROjN4NkWxPVg>
Jurkat NV:xU4JoSXCxcITvd4l{KEG|c3H5 NUfi[|NuOTJwNT21NO69VQ>? NXewTYVvOWh? NFvwNFlld3OnIHTldIVv\GWwdHz5JJN2eHC{ZYPz[ZMhW1CKLXnu[JVk\WRiUHHyMVQh[2ynYY\h[4UtKFCDUmCgZ4xm[X[jZ3WsJGRPSSCocnHncYVvfGG2aX;uMEBidmRibH;zd{Bw\iC4aXHibYxqfHl? NV6wNlFmOjN2NEK5O|Y>
CNE-1 M3r0[mFxd3C2b4Ppd{BCe3OjeR?= MYqyNO69VcLi MWmyOIg> M1fpWolvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= MlL0NlM1OjZ6NUC=
HONE-1 MXjBdI9xfG:|aYOgRZN{[Xl? MoDRNlDPxE4EoB?= MoDENlRp MU\pcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq MoLYNlM1OjZ6NUC=
astrocytes cell MmPDRZBweHSxc3nzJGF{e2G7 MVq0NO69VQ>? M37abVZp NVj2S3E6emWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n MXWyN|QyOTd5OB?=
U-937 Mn;ZRZBweHSxc3nzJGF{e2G7 MXSxNO69VQ>? M4XNbVMxdWmw NHjkVVJxemW4ZX70d{BVVkZvaX7keYNm\CCwZXPyc5B1d3Orcx?= M{jhOVI{PDFyN{S4
MDA-MB-231 Ml7uRZBweHSxc3nzJGF{e2G7 MXyxNFDPxE1? M2DJfVFp NVfZU48zcW6qaXLpeJMhe2Wwc3n0bZpifGmxbjD0c{BVWkGLTDD1dI9vKE2WRFig[I94di2{ZXf1cIF1cW:w NGH4XGwzOzRyOESyPS=>
HeLa  NUL0PYt3SXCxcITvd4l{KEG|c3H5 MkT5NVAx|ryP MUOybC=> MlHzZoxw[2u|IFrSV{0yPSCLbnT1Z4V{KEGyb4D0c5Rq[yCFZXzsJGRm[XSq MoTZNlM{PDRyNEW=
Ec109 NV:xRYh1SXCxcITvd4l{KEG|c3H5 MVyxNO69VQ>? NXLzc4tyPmh? Mnf6Zoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> M4P0T|I{OzN6NU[4
H460  NX\XXW5LSXCxcITvd4l{KEG|c3H5 MYKxNO69VQ>? MUC2bC=> MXHicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MYWyN|M{QDV4OB?=
HeLa  M2DSZWFxd3C2b4Ppd{BCe3OjeR?= MlXrOVDPxE1? M{XtcVEvPWh? M{LyRoFjem:pYYTld:KhS2iuYX35[IliNWmwZIXj[YQh[XCxcITvd4l{ NF7BVY4zOzNyM{iwOC=>
SK-HEP1 M{PpcmFxd3C2b4Ppd{BCe3OjeR?= MWKxNFDPxE1? NVTEfVJPOWh? M4TKcYlvcGmkaYTzJGNzXDFiYXP0bZZifGWmIHPhd5Bie2VvMzygMVctKC16LDCtPUwh[W6mIIDvcJkpSUSSLYLpZo9{\SlicH;sfY1memG|ZR?= NFnhUmczOzNyMk[1NC=>
QGY7701 MonERZBweHSxc3nzJGF{e2G7 MnrHNlXPxE1? NWHrfGpXOS53aB?= NESzOpVqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MU[yN|I1ODB4MR?=
HepG2 M4G0XWFxd3C2b4Ppd{BCe3OjeR?= MofwNlDPxE1? NF7CVmE{OG2rbh?= MV\pcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN M3nwW|I{OjJ2MkO5
U87  MY\BdI9xfG:|aYOgRZN{[Xl? MlnRNlXPxE1? M3jy[VJp NG\ndGRl\WO{ZXHz[ZMhcXOxbHnxeYlzcXSrZ3XubY4hMEmVTDmtbY5lfWOnZDDhdI9xfG:2aXOgZ4VtdCCmZXH0bEwh[nW2IH7veEBv\WO{b4TpZ{Bk\WyuIHTlZZRp M3r0c|I{OjJ7NkK2
HSC-2 NHHIbZlCeG:ydH;zbZMhSXO|YYm= M3Pa[|I2NzVyzszN M3Hq[lFp NWLad4tncW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> M4nTVVI{OTV3MkS4
HSC-4 NVrIN2VTSXCxcITvd4l{KEG|c3H5 Mo[1NlUwPTEQvF2= Mnj1NYg> M{nOeYlvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 MWSyN|E2PTJ2OB?=
CL-1 NF3aXYVCeG:ydH;zbZMhSXO|YYm= NHOxXJczOM7:TR?= MWOxbC=> NGLxW|RjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq MlPLNlMyOzF5OEK=
MEL MXPBdI9xfG:|aYOgRZN{[Xl? M13XPVIx|ryP MVGyOIg> NG\yU|VFVVOR NUXpPJV7cW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= MoL4NlMxOTR6OEe=
Bel-7402  MlLOR4F{eGG|ZTDBZ5RqfmG2aX;uJGF{e2G7 MkjUOVDPxE1? NED0epgzcA>? NInWXllqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ Mn;nNlMxODh5NEK=
Eca-109 NIr1T4FCeG:ydH;zbZMhSXO|YYm= NWrOSmRJOjYQvF2= MlzKN|BucW5? MnfqbY5pcWKrdIOgRmouSjFzLXnu[JVk\WRiY3XscEBl\WG2aB?= NW\RTVl4OjNyN{[5Olc>
MEL MXrBdI9xfG:|aYOgRZN{[Xl? NXzSS3VROjEQvF2= MoTmNYg> MmnySG1UVw>? M{ezVYlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? NXrWSmQzOjNyMUS4PFc>
Bel-7402  MlPhRZBweHSxc3nzJGF{e2G7 MVm1NO69VQ>? MVGybC=> NFr4cYRqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ MYiyN|AxQDd2Mh?=
L929 NH\w[o9HfW6ldHnvckBCe3OjeR?= Mnu1Nk42|ryP M1\VSFFp NILveIJqdmO{ZXHz[ZMhWkmSMTDlfJBz\XO|aX;uJIFv\CCneHHj[ZJj[XSnZDDUUmbPuS2rbnT1Z4VlKG2rdH;jbI9v\HKrYXyg[Jl{\nWwY4Tpc44h[W6mIGLPV{Bxem:mdXP0bY9v NHfwOIozOzByMEWxPC=>
RCC  M3zqc2NmdGxiVnnhZoltcXS7IFHzd4F6 MUexNFDPxE1? MYGyOIg> M1\QW5Jm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= M3nxZ|IzQTlzNEm0
NB2a/d1 Mm[5RZBweHSxc3nzJGF{e2G7 MkTzNVAx|ryP M2rt[FczcA>? M3:4PIF1fGWwdXH0[ZMhe3SjdYLvd5BwemmwZT3pcoR2[2WmIHPhd5Bie2ViYXP0bZZqfHluIGDBVnAtKGGwZDD0ZZUh[2ynYY\h[4U> Mn:4NlI6QDh3NEG=
T cell M4Gw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2yOU0yODEQvF2= M{PL[|I1cA>? MUHkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> NW\obYFOOjJ7OEK1N|g>
K562 NUXFPWF3SXCxcITvd4l{KEG|c3H5 NGrQcnIyODEQvF2= M2PwSVFp NELYbmljdG:la4OgRYJvd2KjdnnzZ5VuyqCILXnu[JVk\WRiYYDvdJRwe2m| NHfKVWEzOjl5MkO3Ni=>
Jurkat  NUTQXodOSXCxcITvd4l{KEG|c3H5 NX7DZ21mPDEQvF2= MVWxbC=> NGTUNIFi[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? MVKyNlk1Ojd|OB?=
BGC-823 NGrIXVRCeG:ydH;zbZMhSXO|YYm= NEfzVpoyODEQvF2= M3exbVFp NVu5eJZkeGG{dHnhcIx6KHKnc3P1[ZMh[2WubIOgZYdicW6|dDDkZY1i\2Vib3[g[IFq\HqnaX6= NVTNWG1VOjJ7Mk[1OFU>
Hep3B MnHBRZBweHSxc3nzJGF{e2G7 MUS1NO69VQ>? MVyxbC=> M1ziNYJtd2OtczDhdI9xfG:|aYOgbY5lfWOnZDDifUBJTUeFcx?= NYjPdJA3OjJ7MkOxOVQ>
LLC-PK1 MX\BdI9xfG:|aYOgRZN{[Xl? NXf5XW1YOjEQvF2= NHrF[VMycA>? MVjwdoV3\W62czDjbZNxdGG2aX6tbY5lfWOnZDDk[Ydz[WSjdHnvckBw\iCDdHe1MEBj\WOuaX6tNUwh[W6mIFH0[|EzKHC{b4TlbY5{ M3SyUFIzQDl4MEO3
A549 MXHBdI9xfG:|aYOgRZN{[Xl? NIH3fog2OM7:TR?= M{XBRlFp NEm4XHdjdG:la4OgeIhmKEKDST3pcoR2[2WmIHHwc5B1d3Orc9Mg M2D1OlIzQDh5MkG1
SGC-7901  M13WdWFxd3C2b4Ppd{BCe3OjeR?= NXrtepp4OTEQvF2= NY\uV41OOjSq NX30TYV3cW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? NYXnfZJ7OjJ6NEi1PVc>
DM6 M4\wU2Fxd3C2b4Ppd{BCe3OjeR?= MVKxNFDPxE1? NUPpe5c{PzKq MmfWZoxw[2u|IHLveIghTTKILUGgZY5lKEV{RoTyMY1m\GmjdHXkJIN6fG:2b4jpZ4l1gQ>? M{S2NFIzQDJ3M{K4
MCF-7, MDA-MB-468, Caco-2 NGm4Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXK1NO69VQ>? NXPCZ2ZmPDiq NFvS[VRqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4> NGT4R2gzOjhyMEm2PC=>
A2750  M3H5RWFxd3C2b4Ppd{BCe3OjeR?= MUGyNO69VQ>? MnrBNog> MnjDSG1UVw>? NWnJ[3Uy[myxY3vzJINie3Cjc3WgZ4xm[X[jZ3Wg[JVzcW6pIHjlcIVv[WyrbjD0doVifG2nboSgZY5lKHKnZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq M4\PelIzPzh2M{[z
U87  NGP1Xm9CeG:ydH;zbZMhSXO|YYm= NVrDU5FVOjEQvF2= M3my[|I1cA>? MlPodoVlfWOnczD0bIUh[XCxcITvd4l{KHKjdHWgbY5lfWOnZDDifUBRVEGE NFTwNYUzOjd5OEe4NC=>
HT1080 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPOOVDPxE1? MnXEO4Q> MkDlbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZ4F2e2WmIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCGQ1GgZY5lKE:PUB?= M1jOdVIzPzRyOUi0
A549  MmflRZBweHSxc3nzJGF{e2G7 NEjkTWs2OM7:TR?= MnHwNog> M2nLUZBienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz MlvnNlI4OjF6MES=
Primary OPC NV;wN4JbSXCxcITvd4l{KEG|c3H5 M17k[lHPxE1? NYTZNndTPmhxMkTo NGnEV5Nz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO= NFO0WGgzOjdyN{O4OS=>
PMNs M2HiOmFxd3C2b4Ppd{BCe3OjeR?= NXjZfFFpPDEQvF2= NWqwcWJkPmh? NXT5fllHTE2VTx?= MYHy[ZZmenOnZDD0bIUh[W2xdX70JI9nKGOuZXH2[YQh[2G|cHHz[U0{KHSxIH7lZZIhfmWqaXPs[UBt\X[nbIO= MmXINlI3QTJ3N{e=
A549  Mnq0RZBweHSxc3nzJGF{e2G7 M4XNeFUx|ryP NYHOZ45POWh? NF;He4xxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEYX;oeY9{cWSnIFm= NELiUHczOjZ6N{[zOS=>
AGS NWPQT2htSXCxcITvd4l{KEG|c3H5 MlfiNlDPxE1? NVywUJlLOTKq NXWw[JFEcW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YheHKxLXPhd5Bie2VvMzDpckBz\XOyb37z[UB1dyC2aHWgSZRQSWNiZoLhZ5Rqd25? NHPZb20zOjZ6N{O5PC=>
shC9  MXXBdI9xfG:|aYOgRZN{[Xl? Mn:1NVDPxE1? MU[xOog> NYPqS|Rx[my3boTzJHNJUCCneIDy[ZN{cW:wIHnuJJNpSzliY3XscJMh\Xiyb4Pl[EB1dyCnaYTo[ZIhWEFib4KgUHBE NFLIWYEzOjZ2MUC5OC=>
primary MEFs MWjGeY5kfGmxbjDBd5NigQ>? MlLYNVJp MnjIxsBqdmO{ZXHz[ZMh\XSxcH;zbYRmNWmwZIXj[YQhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDk[ZBwdGG{aYrheIlwdg>? M3fPWFIzPjF|N{[3
3T9 MEFs MWnGeY5kfGmxbjDBd5NigQ>? MmLxNVZp NUXzRXlycW6lcnXhd4V{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHHmeIVzKGW2b4Dvd4ll\S22cnXheI1mdnR? NU\HNZhPOjJ4MUO3Olc>
3T9 MEFs NYPzbm9STnWwY4Tpc44hSXO|YYm= NXTocm1POTiq MXv1dJJm\3WuYYTld{Bqdmm2aXH0c5Ih[2G|cHHz[U06KGK3dDDkc5dvemWpdXzheIV{KGWoZnXjeI9zKGOjc4Dhd4V{KGGodHXyJIV1d3Cxc3nk[UB1emWjdH3lcpQ> MmLiNlI3OTN5Nke=
MDA-MB-231  NHjYPHVCeG:ydH;zbZMhSXO|YYm= MUiyNO69VQ>? M13pWFRl MkHpdoVlfWOnczD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBu\XSob4LtbY4hfHKnYYTt[Y51KHejczDzbYdvcW[rY3HueIx6 MXKyNlU6OzR2MR?=
C6  MX;BdI9xfG:|aYOgRZN{[Xl? NV;oOnZ[OTEQvF2= NF35VHIzPGh? MVnicI9kc3NidHjlJJN2eHC{ZYPzbZZmKGWoZnXjeEBw\iC2aHWgdIVxfGmmZTDvckB3cWGkaXzpeJk> M{W5VFIzPTh6OUiw
HL-60  MVrBdI9xfG:|aYOgRZN{[Xl? M1Ljd|ExOM7:TR?= NXfHcVBjOjSq NYLTe4ZmcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> NXHsUG9vOjJ3NE[2Olk>
HL-60 M3zhN2Fxd3C2b4Ppd{BCe3OjeR?= MXixNE05OM7:TR?= M1nsUFRp NYjvS|VXcW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB? MoPtNlI2OjN{Mkm=
BCC NULkZ4x3SXCxcITvd4l{KEG|c3H5 NVzUZYJ1PTEQvF2= M4HnSFFp MnX5bY5pcWKrdIOgSGFVWy2vZXTpZZRm\CCpcn;3eIghcW6qaXLpeIlwdg>? MUiyNlUyQTR|Nh?=
RAW 264.7 NFnYW41CeG:ydH;zbZMhSXO|YYm= NHX3[Jg2OC9zMEFOwG0> NW\DSWtNOWh? MlnpZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfHNiRF;OMYlv\HWlZXSgdnJPSSClbHXheoFo\Q>? M1\HWVIzPDlzNEK2
K562 M3PIWGFxd3C2b4Ppd{BCe3OjeR?= NHrWOW4zPc7:TR?= M4qz[VJp NXHDUZdXeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3:teJJm[XSvZX70JJdqfGhiYX31doVve2mwIFegZY5lKFSUQVnM NWn5T2w{OjJ2OEO3O|c>
SGC-7901 MnS0RZBweHSxc3nzJGF{e2G7 M{TCTFIxKM7:TdMg M3vUVVJp M17kNIF1fGWwdXH0[ZMhUDKRMtMgc5IhXE6IIN8xMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXNiYYOge4VtdCCjczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> NF3MUGozOjR5MUW4PS=>
PC3 NV24bGs1SXCxcITvd4l{KEG|c3H5 NGq4bHQyOM7:TR?= M4rz[FRp MmHkZ492dnSncoOg[oxifm:lb4jp[E1qdmS3Y3XkJINie3Cjc3WtdoVt[XSnZDDhdI9xfG:|aYO= NF[0THozOjR5MUm3OC=>
SMMC-7721 NUjVN4pwSXCxcITvd4l{KEG|c3H5 M3XsXlUx|ryP NWXhVHl3PDiq M1TUV4F1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| MmXQNlI1PjV6M{O=
HeLa  MXPBdI9xfG:|aYOgRZN{[Xl? MV61NOKh|ryP MYK0M|hp M4XVNolvcGmkaYTzJHNVWy2rbnT1Z4VlKGyjdHWtdIhie2ViYYDvdJRwfGmlIHX2[Y51ew>? M13lSVIzPDZyNUC0
HeLa  NHHVW25CeG:ydH;zbZMhSXO|YYm= NWTNSmpTPTEEoN88US=> NF7QOlkycA>? Mnjad5VxeHKnc4Pld{B1cGViRmLBVE1qdmS3Y3XkJIFk[3WvdXzheIlwdiCxZjDhco5mgGmwIG[gdI9{cXSrdnWgZ4VtdHN? NEXyZVEzOjR2OUS0NC=>
T47D  M3\R[2Fxd3C2b4Ppd{BCe3OjeR?= NF31OmUyODEQvF2= MmPDNYg> NUHDc|hZ[myxY3vzJJRp\SCpZX7ldoF1cW:wIH;mJGUu[2GmL1PUSlIh[nliU2TT M{jyelIzPDBzMU[4
HeLa  MWfBdI9xfG:|aYOgRZN{[Xl? NF\XfJY{OM7:TR?= M2fmc|Rp NInoS27DqGmwY4LlZZNmeyC2aHWg[4Vv\XKjbDDj[YxtKH[rYXLpcIl1gSB2ODDoJIFnfGW{IIDoc5Rw\HmwYX3pZ{B1emWjdH3lcpTDqA>? M3;6T|IzOzl2MkS4
HCC MWrBdI9xfG:|aYOgRZN{[Xl? MlPYNlAh|ryPwrC= NYj0bGQ5Omh? NEL0ZppifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> MXOyNlM1Ojd|Mh?=
mESCs M{LUUWFxd3C2b4Ppd{BCe3OjeR?= MVWyMlXPxE1? NFrPPZgzcA>? NVjEbXZ6cW6qaXLpeJMhfGinIF7hSk1u\WSrYYTl[EBk[XOyYYPlJIFkfGm4YYTpc44> NHTQNFMzOjJ6NUK3OC=>
EMT-6  NEHoR3VEgXSxdH;4bYNqfHliQYPzZZk> MY[xNFDPxE1? MlTlNYg> Mne4dIFzfGmjbHz5JIJtd2OtZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KHOrcnHt[ZNqdmV? NUjEOXlOOjJ{NUG5NlE>
MCF7 MnPiRZBweHSxc3nzJGF{e2G7 MV[1NOKh|ryP MV:xbC=> MlnpbY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NWLQOJFoOjJ{MkOzOFU>
K562 M3rpR2Fxd3C2b4Ppd{BCe3OjeR?= MnTmNlAh|ryPwrC= NUCxUHBEPDiq MnTXSG1UVw>? NEjRTlBjdG:la4OgcIFx[XSrbnniMYlv\HWlZXSgbY5pcWKrdHnvckBw\iC4aXHibYxqfHliYX7kJIFxd3C2b4Ppd{BqdmS3Y4Tpc44> M4XrN|IzOjF4MUW4
Molt4-hyg M{[2OmFxd3C2b4Ppd{BCe3OjeR?= NHy1TowyOM7:TR?= MXiwMlVp M3;1fYJtd2OtczDmZZJv\XOxbD3pcoR2[2WmIHPhd5Bie2VvMz3sbYtmKGGldHn2bZR6 M1L0Z|I3Ojd3OEGx
HeLa NV;o[ZE{SXCxcITvd4l{KEG|c3H5 NV;Nd4tJOTEQvF2= MmG2NE42cA>? MYLpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1cGViY3;tZolv\WRidILlZZRu\W62IIfpeIgh\2:vaYPpckBPKGGwZDDUVmFKVA>? NGj2RWczOjF5OU[2NS=>
Jurkat T MoDVRZBweHSxc3nzJGF{e2G7 MY[zNO69VQ>? MXWwMlVp M3zMU2ROW09? M3jZS4Jtd2OtczD0bIUhgmm{YX2tbY5lfWOnZDDhdI9xfG:|aYO= M1q2RVIzOTV7OEm4
Neutrophil MX\BdI9xfG:|aYOgRZN{[Xl? NHXvOIUzOM7:TR?= MlrWNE42cA>? NGnOblJifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx M1zrPVI3OTl4OES0
HCT116 MkTmRZBweHSxc3nzJGF{e2G7 MVW1NOKh|ryP MXWybC=> NFXwO3Zz\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKh NFPScVAzOjF3OUe1Ni=>
MDA-MB-231  NEi2d5dCeG:ydH;zbZMhSXO|YYm= M17wVFIvPS15LkZOwG0> MWOybC=> MlXMbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhib3[gUWRCNU2ELUKzNUBk\WyuczDpcoR2[2WmIHL5JHNFXCCrbjDhJINwdmOnboTyZZRqd25iZHXw[Y5l\W62IH3hco5meg>? M325RVIzOTF3NUK2
LNCaP MnHsRZBweHSxc3nzJGF{e2G7 NYDOfpI{PDEQvF2= M13uZ|Jp NUTQfJY1cW6qaXLpeJMh[nW2ZXnuJIlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? NIm5dVUzOjFzNEe2OC=>
MB231 MV3BdI9xfG:|aYOgRZN{[Xl? MonLNVAx|ryP NVPre206OWh? MVHEUXNQ M4X5TYFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? MWWyNlEyOjl2MB?=
HCC38  NVLnUY9USXCxcITvd4l{KEG|c3H5 NFHBTGIyODEQvF2= MWmxbC=> MXzEUXNQ NWC4OnZU[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= MXmyNlEyOjl2MB?=
MDA-MB231 Mm\LRZBweHSxc3nzJGF{e2G7 NVP5Nm9EPTEEoN88US=> NFrJXFgzPGh? NYLQdo53TE2VTx?= NVHFRoZT[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NG\ZfYwzOjFyMUOzOS=>
LNCaP M1n3R2Fxd3C2b4Ppd{BCe3OjeR?= Mmn6OVDDqM7:TR?= NH;OOFczPGh? NFz4TVBFVVOR NIXzfXFi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp MUmyNlExOTN|NR?=
HCT116 NXfsXZU2SXCxcITvd4l{KEG|c3H5 NEey[JA2OMLizszN NF7IZY4zPGh? M2H0W2ROW09? NEe1[|Fi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp M3flOVIzOTBzM{O1
Ishikawa  NH74No5CeG:ydH;zbZMhSXO|YYm= MXGyOe69VQ>? M1Pue|I1cA>? MV3y[YR2[2W|IHPlcIwh\GWjdHigZY5lKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFLh[kBCOQ>? NFjJW|MzOjB6OEmxPC=>
 YD-8  MX;BdI9xfG:|aYOgRZN{[Xl? M3XWR|ExOM7:TR?= M4HnblFp M3TDNIlvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN? MXSyNlA5PjF6Mx?=
eosinophil  M1vOfWFxd3C2b4Ppd{BCe3OjeR?= NEHTUnI6OM7:TR?= MUiyOIg> MXnpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?= NVXFd41JOjJyN{mzN|Q>
L929 NEf1TXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvTfpZzOi53zszN MnfqNlRp Mn7SbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gdE1xOzhiYX7kJG5HNc78QjD0c{BifWevZX70JHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>? NHfZOHAzOjB{N{C5Oy=>
YD-8  M3PGUGFxd3C2b4Ppd{BCe3OjeR?= M1TXSVExOM7:TR?= MWqxbC=> MlTUZoxw[2u|IITo[UBIWy2KQ3ytbY5lfWOnZDDhdI9xfG:|aYO= MVKyNlAzODB5OB?=
HBx MWLBdI9xfG:|aYOgRZN{[Xl? NIS2WGgzPc7:TR?= M4O0NVQ5cA>? NEj6WVRFVVOR NYO1cIRLemWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> NXHLPVFZOjJyMkCwO|g>
U937  M4H4b2Fxd3C2b4Ppd{BCe3OjeR?= MYC1NOKh|ryP MXSxbC=> MUfpcohq[mm2czDISk1qdmS3Y3XkJIFxd3C2b4Ppd:Kh M2fZdVIyQTl6N{Ox
HL60 NUT2WG5PSXCxcITvd4l{KEG|c3H5 MWq0NO69VQ>? MlnzOFBucW5? NX\XelIxTE2VTx?= NHfOeopjdG:la4OgRm5FSyClb33wc5Vv\HNiaX7keYNmKGW6cH;zeZJmKG:oIIDoc5NxcGG2aXT5cJNmemmwZTDhcoQhTE6DIH\yZYdu\W62YYTpc44> M3LWU|IyQTh|Mkm2
M-14 MoPERZBweHSxc3nzJGF{e2G7 NEDCbGszPc7:TR?= M1Wye|AvPWh? NUW3bnBwyqCrbnjpZol1eyCkb4ToJJRp\SClcoXk[UBmgHS{YXP0MUBidmRiY3;tdI92dmRvaX7keYNm\CCjcH;weI9{cXN? NX;BUm1jOjF7NUS5OVk>
SK-BR-3 NXTVOWI5SXCxcITvd4l{KEG|c3H5 MnzGOVDDqM7:TR?= NW[5foNMOmh? MlvnZoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u NXzhZVVEOjF7MEGzPFY>
MDA-MB-468 NYrzelFbSXCxcITvd4l{KEG|c3H5 NFzMOGI2OMLizszN MWmybC=> MWjicI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= M163UVIyQTBzM{i2

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products0

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID